Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,043 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Debulking Surgery for Ovarian Cancer
Interventions
Ensure Surgery Immunonutrition Shake supplements, Daily Food Intake form
Dietary Supplement · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain

NCT01189071
Conditions
Overactive Bladder, Renal Colic, Pain, Postoperative
Interventions
Darifenacin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Conditions
Resectable Pancreatic Cancer
Interventions
Gemcitabine and Abraxane
Drug
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Minneapolis, Minnesota + 1 more
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Preoperative Methadone, Preoperative Oxycodone
Drug
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 89 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Breast Lumpectomy, Laparoscopic Cholecystectomy, Inguinal Hernia Repair
Interventions
Active de-Implementation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
trametinib, fluorouracil, radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
4
States / cities
St Louis, Missouri • Buffalo, New York • Columbus, Ohio + 1 more
Conditions
Astigmatism
Interventions
enVista® One-Piece Hydrophobic Acrylic Toric IOL, enVista control lens
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Irvine, California
Conditions
Surgical Procedure
Interventions
Marking abdomen
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Esophageal Carcinoma
Interventions
Tetrathiomolybdate (TM), Radiation, Surgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
Interventions
Ferumoxytol, Nanoparticle MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pediatric Emergence Agitation and Pain
Interventions
Midazolam, Game Boy
Drug · Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
4 Years to 12 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Pancreatic Cancer
Interventions
erlotinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Urology
Interventions
Preoperative Outreach
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer
Interventions
Cisplatin, Rucaparib
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more
Conditions
Thoracic, Colorectal Disorders
Interventions
observational study
Other
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Manhasset, New York • Columbus, Ohio + 1 more
Conditions
Anxiety
Interventions
midazolam or GameBoy or parental presence
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
4 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma, Malignant Astrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • New York, New York + 1 more
Conditions
Glioblastoma Multiforme, Meningioma
Interventions
Ribociclib
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Carcinoma, Non Small Cell Lung
Interventions
gemcitabine, carboplatin, cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 3 Interventional Results available

Prevention of Post-operative Urinary Retention

NCT02486653
Conditions
Urinary Retention, Urinary Tract Infections
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Hysterectomy, Gender Affirming Surgery
Interventions
Educational Handout
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Rectal Neoplasms
Interventions
External beam radiation, Oxaliplatin, Leucovorin, 5-FU, Capecitabine
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension

NCT06258785
Conditions
Postoperative Urinary Retention, Sacrospinous Vaginal Vault Suspension, Reconstructive Pelvic Surgery
Interventions
Tizanidine
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Skokie, Illinois